Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease

Kaohsiung J Med Sci. 2022 Oct;38(10):1012-1019. doi: 10.1002/kjm2.12580. Epub 2022 Aug 22.

Abstract

Metabolic-associated fatty liver disease (MAFLD) is a growing global problem associated with increasing obesity prevalence. Lifestyle modifications are currently recommended, including weight reduction, exercise, and diet control. This study evaluated the short-term effect of lifestyle modifications on transient elastography (TE) values in an obese population with MAFLD. Thirty-two MAFLD patients were recruited for this prospective study and all subjects participated in a 3-month program of lifestyle modification. Sequential demographic parameters and biochemical tests were compared before and after program completion. Liver fat and fibrosis changes were measured using TE with controlled attenuated parameter (CAP) and liver stiffness measurements (LSM). The mean age was 38.7 years old (10 males). The body weight (88.09 kg vs. 80.35 kg), body mass index (32.24 kg/m2 vs. 29.4 kg/m2 ), waist (103.19 cm vs. 95.75 cm), and hip circumference (111.67 cm vs. 104.75 cm), and blood pressure (128/78 mmHg vs. 119/71 mmHg) significantly improved before and after the intervention, respectively. Aspartate aminotransaminase (24.06 U/L vs. 18.91 U/L), alanine aminotransaminase (33 U/L vs. 23.72 U/L), creatinine (0.75 mg/dl vs. 0.70 mg/dl), cholesterol (176.41 mg/dl vs. 166.22 m/dl), gamma-glutamyl transferase (26.59 IU/L vs. 19.81 IU/L), and low-density lipoprotein cholesterol (115.63 mg/dl vs. 103.19 mg/dl) also improved after the 3-month intervention. The average CAP significantly decreased after intervention (297.5 dB/m vs. 255.0 dB/m), however, no significant difference in LSM was observed (5.24 kPa vs. 4.82 kPa). The current study suggests that short-term lifestyle modification can effectively improve hepatic steatosis, and TE may serve as a monitoring tool for therapeutic intervention.

Keywords: fatty liver; lifestyle intervention; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; weight loss.

MeSH terms

  • Adult
  • Alanine
  • Aspartic Acid
  • Creatinine
  • Elasticity Imaging Techniques*
  • Female
  • Humans
  • Lipoproteins, LDL
  • Liver / pathology
  • Liver Cirrhosis* / complications
  • Male
  • Non-alcoholic Fatty Liver Disease* / complications
  • Obesity / complications
  • Prospective Studies
  • gamma-Glutamyltransferase

Substances

  • Lipoproteins, LDL
  • Aspartic Acid
  • Creatinine
  • gamma-Glutamyltransferase
  • Alanine